Registration

Fee: There is no fee for this program.

Advanced registration is required.

To Register go to www.wnerxce.org/user/login.

There are no walk-ins or telephone reservations.

This program is not accredited for pharmacy technicians.

Deadline for registration is Tuesday, May 30, 2017.

Requirements for Credit:

• Upon completion of the program, attendees will earn 6 contact hours of ACPE accredited Continuing Pharmacy Education. Participants will be required to insert an activity specific code number and successfully complete the activity learning evaluation form. Instructions for accessing this website will be given to participants on the day of the program.

• Participants must have an NABP ID number to document credit on the CPE Monitor System of the National Association of Boards of Pharmacy.

• Participant names will be checked against program attendance sheets for verification of attendance.

• Participants have 30 days to complete assessment of learning/evaluations. After 30 days from June 6, 2017, no credit will be available for this program.

• Credits will be directly transferred to the National Association of Boards of Pharmacy CPE Monitor System. No Statements of Credit will be issued.

Evaluation: All participants will have the opportunity to review the educational sessions and speakers and to identify future educational needs.

For directions to the University, go to: www.wne.edu/visiting.

For additional information and questions, please contact Dr. Shusen Sun at ssun@wne.edu.

For registration questions, please contact Joanne Moore at joanne.moore@wne.edu or 413-796-2046.

Western New England University College of Pharmacy is proud to sponsor this Continuing Education Conference

Part of the Mission of the Western New England University College of Pharmacy is to enhance the knowledge base of the pharmacy profession through teaching, service, practice, research, and scholarly activity. Through this Continuing Education Conference, the College of Pharmacy demonstrates our commitment to lifelong learning.

This program will provide updates and strategies on enhancing medication safety.

Continuing Pharmacy Education conferences are a way to continue your own professional development.

ENHANCING MEDICATION SAFETY 2017 for Registered Pharmacists

Tuesday, June 6, 2017
8:15 a.m. to 4:30 p.m.
Western New England University
Rivers Memorial Hall
Agenda

8:15 a.m. to 8:50 a.m. 
Registration/Continental Breakfast

8:50 a.m. to 9:00 a.m. 
Welcome and Remarks
Evan Robinson, PhD, RPh
Dean, Western New England University College of Pharmacy

9:00 a.m. to 10:00 a.m. 
Safe Practices of Medication Use in the Hospital Setting

10:00 a.m. to 11:00 a.m. 
Less Is More: Deprescribing in Older Adults

11:00 a.m. to 11:15 a.m. 
Coffee Break

11:15 a.m. to 12:15 p.m. 
Less Is More: Deprescribing in Older Adults

12:15 p.m. to 1:15 p.m. 
Lunch

1:15 p.m. to 2:15 p.m. 
Taking Care of Two: The Management of Mood Disorders During Pregnancy

2:15 p.m. to 2:30 p.m. 
Coffee Break

2:30 p.m. to 3:30 p.m. 
Antidotes and Supportive Care Agents in Oncology

3:30 p.m. to 4:30 p.m. 
Drug Toxicities: Lithium, Valproate, and Phenytoin

4:30 p.m. 
Closing Comments—Adjourn

Learning Objectives and Speaker Credentials

Safe Practices of Medication Use in the Hospital Setting
Janet Kozakiewicz, MS, PharmD, FASHP
Director of Pharmacy
Yale New Haven Hospital

• Define the closed-loop process for medication management.
• Differentiate the concepts of Root Cause Analysis (RCA), Common Cause Analysis (CCA), and Failure Mode and Effects Analysis (FMEA).
• Outline how the use of medication safety dashboards can be used to create a shared accountability model.

Less Is More: Deprescribing in Older Adults
Kristina Shvets, PharmD, BCPS
Director, PGY2 Internal Medicine Pharmacy Practice Residency
Yale New Haven Hospital

• Outline how the use of medication safety dashboards can be used to create a shared accountability model.
• Differentiate the concepts of Root Cause Analysis (RCA), Common Cause Analysis (CCA), and Failure Mode and Effects Analysis (FMEA).
• Outline how the use of medication safety dashboards can be used to create a shared accountability model.

Oral Chemotherapy: Is “Easier” Safer?

Kristen Rychalsky, PharmD, BCPS, BCOP
Oncology Clinical Pharmacist
Smilow Cancer Hospital—Yale New Haven Health

• Identify common oral chemotherapy agents and indications for use.
• Define best practices for ensuring safety in the medication use process for oral chemotherapy.
• Describe important side effects, drug interactions, and counseling points for patients taking oral chemotherapy medications.
0576-0000-17-008-L05-P—1 contact hour—knowledge based

Taking Care of Two: The Management of Mood Disorders During Pregnancy
Chandra Cooper, PharmD, BCPP
Coordinator, Training & Education
Director, PGY-2 Psychiatric Pharmacy Residency Program
Yale New Haven Hospital

• Describe the clinical presentation and incidence of mood disorders during pregnancy.
• Define the risks and benefits of using psychotropic medications to manage depression and bipolar disorder during pregnancy.
• Differentiate between the historic and updated FDA pregnancy category labeling.
• Apply practice guidelines and literature findings to make effective medication selections in the management of depression and bipolar disorder during pregnancy.
0576-0000-17-009-L01-P—1 contact hour—application based

Antidotes and Supportive Care Agents In Oncology

Shuxen Sun, PharmD, BCPS
Clinical Assistant Professor
College of Pharmacy, Western New England University
Clinical Pharmacy Specialist—Emergency Medicine

• Describe mechanisms of actions and pharmacokinetics relating to the antidotes/reversal agents used in oncology setting.
• List dosing and monitoring parameters for the antidotes/reversal agents discussed.
• Make sound recommendations regarding the appropriate stocking and use of the antidotes/reversal agents discussed.
0576-0000-17-010-L01-P—1 contact hour—knowledge based

Drug Toxicities: Lithium, Valproate, and Phenytoin
Dayne Laskey, PharmD, DABAT
Assistant Professor
University of Saint Joseph School of Pharmacy

• Describe symptoms of supratherapeutic drug toxicity related to VPA, PHY, and Li.
• Describe mechanisms and pharmacokinetics relating to VPA, PHY, and Li.
• Make sound patient care decisions regarding patients with VPA, PHY, and Li toxicity.
0576-0000-17-011-L01-P—1 contact hour—knowledge based

Statement of Disclosure

In accordance with the Standards for Continuing Pharmacy Education of the Accreditation Council for Pharmacy Education, Western New England University College of Pharmacy will disclose any interest or affiliation a speaker might have with a supporting commercial organization. Such disclosure will be made available on the day of the program. Acknowledgement of financial support will be made on the day of the program.

Accreditation Statement

Western New England University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is supported by an unrestricted educational grant from BTG International Inc.